Literature DB >> 2068161

A phase I/II study of 131I mIBG in chemo-resistant neuroblastoma. The United Kingdom Children's Cancer Study Group (UKCCSG).

I J Lewis1, L S Lashford, S Fielding, M A Flower, D Ackery, J Kemshead.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2068161

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  4 in total

Review 1.  Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review.

Authors:  J T Kemshead; K Hopkins
Journal:  J R Soc Med       Date:  1993-04       Impact factor: 18.000

2.  A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.

Authors:  Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; Minna Koskenvuo; Jelena Rascon; Max van Noesel; Per Grybäck; Joachim Nilsson; Arthur Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Dan Granberg; Mark Gaze; Jakob Stenman
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

3.  131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

Authors:  M N Gaze; R J Mairs; S M Boyack; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

Review 4.  Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Authors:  Keri A Streby; Nilay Shah; Mark A Ranalli; Anne Kunkler; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.